Longeveron Inc
LGVN0.765USD
-0.035-4.36%
交易中 （美东）报价延迟15分钟
11.56M总市值
亏损市盈率 TTM
关于 Longeveron Inc 公司
Longeveron Inc. 是一家临床阶段的生物技术公司。该公司专注于开发针对特定衰老相关和危及生命的疾病的细胞疗法。该公司的主要研究产品是 LOMECEL-B 细胞疗法产品 (Lomecel-B)，该产品源自培养扩增的药用信号细胞 (MSC)，这些细胞来源于年轻健康成人捐赠者的骨髓。该公司主要专注于三种管线适应症，包括左心发育不全综合征 (HLHS)、阿尔茨海默病 (AD) 和衰老相关虚弱症。其 Lomecel-B 具有多种作用机制，包括促血管、促再生、抗炎和组织修复和愈合作用，可在一系列疾病领域中应用。该公司与两家供应商签订了骨髓供应合同：俄克拉荷马州血液研究所和 Vista Health Research。
Longeveron Inc简介
公司代码LGVN
公司名称Longeveron Inc
上市日期Feb 12, 2021
CEOMr. Wa'el Hashad
员工数量25
证券类型Ordinary Share
年结日Feb 12
公司地址1951 NW 7th Ave
城市MIAMI
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编33136
电话13053027158
网址https://www.longeveron.com/
公司代码LGVN
上市日期Feb 12, 2021
CEOMr. Wa'el Hashad
Longeveron Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Dr. George Paletta
Dr. George Paletta
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
业务USD
名称
营收
占比
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
暂无数据
业务
地区
业务USD
名称
营收
占比
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
股东统计
更新时间: 10月29日 周三
更新时间: 10月29日 周三
持股股东
股东类型
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
6.01%
Armistice Capital LLC
3.45%
Lehr (Paul T)
1.66%
Hashad (Mohamed Wa'el Ahmed)
1.59%
Hare (Joshua M)
1.29%
其他
85.99%
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
6.01%
Armistice Capital LLC
3.45%
Lehr (Paul T)
1.66%
Hashad (Mohamed Wa'el Ahmed)
1.59%
Hare (Joshua M)
1.29%
其他
85.99%
股东类型
持股股东
占比
Individual Investor
9.26%
Corporation
6.01%
Hedge Fund
3.96%
Investment Advisor
1.66%
Investment Advisor/Hedge Fund
1.09%
Venture Capital
0.25%
Bank and Trust
0.02%
其他
77.75%
机构持股
更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
58
1.37M
6.98%
+569.67K
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lincoln Alternative Strategies LLC
1.18M
6.01%
+1.18M
--
Aug 08, 2025
Armistice Capital LLC
676.23K
3.45%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
330.30K
2.42%
+100.44K
+43.69%
Jul 15, 2025
Hashad (Mohamed Wa'el Ahmed)
310.90K
1.59%
+166.85K
+115.83%
Jul 15, 2025
Hare (Joshua M)
253.07K
1.29%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
179.52K
0.92%
+17.00K
+10.46%
Jul 15, 2025
Locklear (Lisa)
164.30K
0.85%
+11.77K
+7.71%
Aug 11, 2025
The Vanguard Group, Inc.
144.27K
0.74%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
141.50K
0.72%
+770.00
+0.55%
Jun 30, 2025
Agafonova (Nataliya)
152.03K
1.12%
+94.57K
+164.57%
Jul 15, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
公告日期
类型
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
